Impact of the amount of parathyroid autotransplantation in total parathyroidectomy for secondary hyperparathyroidism: a prospective randomized trial Authors: Pichit Sittitrai, Danunuch Pasupat, Donyarat Ruenmarkkaew, Hanpon Klibngern, Tapanut Ariyanon, Orapan Sangiamporn, Weerachai Watcharatsiriyuth Published: 2025 ABSTRACT This prospective randomized study evaluated the effect of the number of transplanted parathyroid fragments on parathyroid hormone (PTH) levels and clinical outcomes in total parathyroidectomy with autotransplantation for secondary hyperparathyroidism (SHPT). Patients were assigned to have either 20 or 45 fragments of parathyroid transplantation. Sixty-three patients were included in the 20-fragment group and 64 in the 45-fragment group. With calcium and vitamin D intake and serum calcium level adjustment, mean PTH levels in the 45-fragment group were higher than the 20-fragment group, with a significant difference at the 12th month (43.79 pg/mL vs. 32.82 pg/mL, p = 0.044). Mean PTH levels were within normal range in both groups at all follow-up visits, and the differences between groups gradually decreased over time. Bone pain and skin pruritus were significantly less in the 45-fragment group only at the 12th and 18th months. One patient in the 20-fragment group had recurrent hyperparathyroidism and was successfully treated with the autograft removal. Two patients in the 20-fragment and one patient in the 45-fragment group developed hypoparathyroidism. Recurrent hyperparathyroidism and hypoparathyroidism rates are low compared with previous studies. In conclusion, both 20 and 45 parathyroid fragment autotransplantation following total parathyroidectomy appear to be similarly effective for SHPT treatment.Trial registration The study was registered in the Thai Clinical Trial Registry with a Unique Identifying Number or registration ID: TCTR20210821001. (date of first registration: 27/06/2019). Introduction Secondary hyperparathyroidism (SHPT) is a common consequence of chronic kidney disease (CKD) as an adaptive response to the maintenance of calcium and phosphorus homeostasis. It results in parathyroid gland hyperplasia and parathyroid hormone (PTH) hypersecretion1–4. The Kidney Disease: Improving Global Outcomes (KDIGO) clinical guideline recommends using dietary control and medications, including active vitamin D compounds, phosphate binders, and calcimimetics, to lower PTH levels for the management of SHPT in hemodialysis patients1,5. However, while medications have clinical benefits in normalization of electrolytes and lowering PTH, their long-term survival benefit cannot be demonstrated by current evidence, and they are ineffective after a period of application6. Parathyroidectomy is indicated for patients with refractoriness or intolerance to medical treatment, which is required in about 15% of patients after 10 years and 38% of patients after 20 years of ongoing dialysis therapy2,3,7. Successful parathyroidectomy that achieves a sustained decrease in PTH levels can ameliorate SHPT-related symptoms, decrease the risk of life-threatening complications, and improve health-related quality of life and survival2. Most patients with SHPT have multiple parathyroid gland abnormalities, for which the surgical options are subtotal or total parathyroidectomy with or without autotransplantation2,3. A meta-analysis showed that in comparison with subtotal parathyroidectomy (SPTX), total parathyroidectomy with autotransplantation (TPTX-AT) has a lower risk of recurrent hyperparathyroidism but a higher incidence of postoperative hypoparathyroidism8. In comparison with total parathyroidectomy (TPTX) alone, TPTX-AT increased the risk of recurrent hyperparathyroidism. However, it has been shown to potentially reduce the risk of postoperative hypoparathyroidism in three meta-analyses4,9,10. In addition, postoperative low PTH levels may result in adynamic bone disease, causing fractures, vascular calcifications, and bone pain11. A recent network meta-analysis comparing these three surgical procedures reported that TPTX-AT is recommended due to its unique advantages in a low rate of hypoparathyroidism, whilst recurrent disease can be safely managed by removing transplanted parathyroid under local anesthesia. Furthermore, cryopreserved parathyroid tissue is not required for subsequent autotransplantation later in the case of persistent hypoparathyroidism3. In TPTX-AT, fragments of the parathyroid gland are implanted into various sites, including the brachioradialis muscle, the anterior tibialis muscle, the pectoral muscle, the sternocleidomastoid muscle, or the subcutaneous tissue to preserve the parathyroid function12,13. However, this procedure poses non-negligible risks of both postoperative hypoparathyroidism and recurrent hyperparathyroidism4,12,13. The optimal amount of implanted parathyroid tissue balancing these risks is still controversial. Although many studies used 20–25 mg of the parathyroid tissue14–18, there are studies which used 50–60 mg13,19–25, or even 90 mg of the parathyroid26. The objective of this randomized trial was to evaluate the impact of the amount of transplanted parathyroid tissue on the level of postoperative PTH in SHPT patients who underwent total parathyroidectomy with 25 mg (20 pieces of 1 mm3 of transplanted parathyroid tissue) or 60 mg (45 pieces of 1 mm3 of transplanted parathyroid tissue). The secondary objective was to compare postoperative improvement of clinical symptoms of hyperparathyroidism (bone pain, muscle weakness, and pruritus) and the rates of persistent or recurrent hyperparathyroidism, reoperation, and hypoparathyroidism between the two groups. Materials and methods Patients and study design This prospective randomized controlled trial complied with the guidelines for Good Clinical Practice and the Declaration of Helsinki and was approved by the Institutional Ethics Committee (Approval number: 089/2019). The study has been reported per the Consolidated Standards of Reporting Trials (CONSORT) Guidelines. Patients were recruited, managed, and followed at the Department of Otolaryngology of our institution between April 2019 and April 2025. All patients who agreed to participate in the study signed an informed consent form before enrollment. The inclusion criteria were patients aged more than 18 years with secondary hyperparathyroidism and had indications for parathyroidectomy, including (1) refractory or intolerance to medical therapy (i.e., calcimimetics and vitamin D analogs), (2) persistently elevated PTH values > 800 pg/ml (> 6 months), (3) persistent hypercalcemia or hyperphosphatemia (corrected serum calcium > 10.2 mg/dL or phosphorus > 5.5 mg/dL), (4) erythropoietin-resistant anemia, (5) patients with nodular hyperplastic glands (confirming on imaging, gland volume > 500 mm3, or glands > 1 cm in long diameter), and (6) evidence of calciphylaxis2. Patients were excluded from the study if they had a history of previous neck irradiation or thyroid/parathyroid surgery, or could not identify all four parathyroid glands during the operation. Patients were treated and followed up on for renal conditions and hyperparathyroidism at our institution’s Division of Nephrology of the Department of Internal Medicine. Nephrologists made the decision which regard to surgical referral. Preoperative demographic and clinical data, including age, gender, duration of renal failure and hemodialysis, laboratory results (corrected calcium (Ca), intact parathyroid hormone (PTH), albumin, phosphorus, magnesium, alkaline phosphatase, and creatinine levels), vocal cord function, and symptoms of hyperparathyroidism, including bone pain, muscle weakness, and pruritus (Visual Analog Scale (VAS) score 0–10) were recorded. Randomization The patients were randomly assigned to 1 of 2 treatment groups in accordance with a computer-generated randomization schedule with an equal probability of assignment to have total parathyroidectomy with autotransplantation of either 20 fragments of 1 mm³ (approximately 25 mg) of parathyroid tissue (20-fragment group) or 45 fragments of 1 mm³ (approximately 60 mg) of parathyroid tissue (45-fragment group). Opaque envelopes were used to conceal identity and blind the sequence of treatment. Patients and outcome assessors were blinded to the randomized groups. Surgical procedures Preoperative parathyroid identification imaging consisted of ultrasound, CT scan, MRI, or Tc-99 m Sestamibi scan. Total parathyroidectomy was performed under general anesthesia by a single surgeon. With a low collar incision, strap muscles were incised in the midline to expose the thyroid gland. Both recurrent laryngeal nerves were identified and preserved. All 4 (or more) parathyroid glands were identified and excised. Transcervical thymectomy on one side was performed if fewer than two glands were found on the respective side or if palpation revealed a suspicious nodule within the thymus13,18,22. Frozen sections were sent to confirm the removal of the parathyroid glands. The average weight of diffuse and nodular parathyroid hyperplasia is 1.26 mg/mm327. In addition, from our data, 20 fragments of a volume of 1 mm3 weighed approximately 25 mg, and 45 fragments weighed approximately 60 mg. Autotransplantation was performed by trimming the most normal-appearing parathyroid gland to a size of 1 mm x 1 mm x 1 mm. After that, 20 pieces of tissue were implanted in the tibialis anterior muscle pocket. The reason for choosing the tibialis anterior was that most of our patients had arteriovenous shunting in both arms or planned to have shunting in the other arm, and it is also a safe and successful site for autotransplantation13. In addition, the autograft function could be effectively assessed using the modified Casanova test13,28. In the patient group with 45 parathyroid fragments implantation, the other 25 pieces were placed rostrally in the second muscle pocket, 2 cm apart in the same skin incision. The pockets were closed and marked with non-absorbable sutures, with 1 and 1.5 cm long at the 20-fragment and 25-fragment pockets, respectively (Fig. 1). Fig. 1Parathyroid autotransplantation: four parathyroid glands were identified and excised (A), the most normal-appearing parathyroid gland was trimmed to a size of 1 mm x 1 mm x 1 mm for 20 pieces and 25 pieces in the 45-fragment group (B), parathyroid fragments were implanted in the tibialis anterior muscle pockets (C), and the pockets were closed and marked with non-absorbable sutures, with 1 and 1.5 cm long at the 20-fragment and 25-fragment pockets, respectively (D). Parathyroid autotransplantation: four parathyroid glands were identified and excised (A), the most normal-appearing parathyroid gland was trimmed to a size of 1 mm x 1 mm x 1 mm for 20 pieces and 25 pieces in the 45-fragment group (B), parathyroid fragments were implanted in the tibialis anterior muscle pockets (C), and the pockets were closed and marked with non-absorbable sutures, with 1 and 1.5 cm long at the 20-fragment and 25-fragment pockets, respectively (D). Outcome assessment Surgical wound complications, vocal cord function, signs and symptoms of hypocalcemia, and laboratory results were recorded postoperatively. Calcium and vitamin D supplements were administered immediately after surgery. Serum calcium levels were monitored at 6, 12, and 24 h and then daily until stabilized. When the serum calcium concentration dropped below 7 mg/dL, 10% calcium gluconate was administered intravenously to maintain serum calcium at more than 7.5 mg/dL. Then, intravenous calcium was gradually reduced with the addition of oral calcium carbonate combined with calcitriol until the serum calcium was maintained between 7.5 and 10.2 mg/dL. Follow-up visits were performed at the 1st, 3rd, 6th, 12th, 18th, 24th, and 36th months after surgery with laboratory results (Ca and PTH levels), symptoms of hyperparathyroidism (bone pain, muscle weakness, and pruritus), surgical complications, and current specific medication (calcium and vitamin D) all being recorded. Persistent hyperparathyroidism was defined as a PTH level higher than 200 pg/mL within 6 months after surgery, whereas recurrent hyperparathyroidism was defined as a PTH level rising above 200 pg/mL after 6 months. Meanwhile, hypoparathyroidism was diagnosed if the PTH level was lower than 15 pg/mL14,21. A modified Casanova test was carried out in patients diagnosed with recurrent hyperparathyroidism to determine the source of PTH secretion. After padding the thigh with cotton wool, a pneumatic tourniquet was placed. The tourniquet was inflated between 30 and 50 mmHg over the systolic blood pressure. The lack of a dorsalis pedis pulse was assessed. Ischemia of the lower limb was maintained for 15 min. Blood samples were obtained from the arm before the ischemic period, during the ischemic period (at 15 min), and 10 min after deflation of the tourniquet. The source of PTH secretion was defined according to the time course of PTH levels during ischemia as follows: a PTH decrease of more than 50% of the pre-ischemic value (test positive) indicates the source at the tibia, whereas a PTH decrease of less than 20% of the pre-ischemic value (test negative) indicates the neck or mediastinum origin. A PTH decrease of more than 20% and less than 50% indicates an undefined source of PTH secretion13,17,28. Statistical analysis Sample size calculation was based on previous studies and our previous collection of data of PTH level at baseline and 12 months postoperatively between autotransplantation of 15–20 pieces of 1 mm3 (approximately 20–25 mg) (1553.08 ± 478.28 pg/mL and 112.46 ± 37.27 pg/mL) and 45 pieces of 1 mm3 (approximately 60–80 mg) (1875.85 ± 288.34 pg/mL and 143.27 ± 28.64 pg/mL) of parathyroid tissue16,29. With an alpha value of 0.05 and 90% power, the sample size needed was 61 patients in each group. Assuming a 10% dropout, a sample size of 132 patients (66 patients in each group) was required for comparing the two-independent mean values. Statistical analyses were performed using SPSS, version 22 for Windows (IBM Corporation, Armonk, NY, USA). Continuous variables were compared using Student’s t-test or Mann-Whitney U test, and categorical variables were compared using the Chi-Square test or Fisher’s exact test as appropriate. Multivariable linear regression analysis was used to determine the effect of procedural techniques on the postoperative PTH levels at each follow-up visit by adjusting for the calcium and vitamin D intakes and serum calcium levels. Results are presented as mean differences or coefficients and 95% confidence interval (CI). Statistical significance was considered for p-values less than 0.05. Results Patient’s characteristics One hundred and thirty-eight patients were assessed for eligibility for inclusion in the study. Patient flow through the trial is summarized in the CONSORT diagram (Fig. 2). Six patients were excluded; 4 had conditions unsuitable for surgery, and 2 declined surgery. One hundred and thirty-two patients were eligible for inclusion and were randomized. Of these, 2 patients in each group were lost to follow-up. In addition, in 1 patient in the group with 20 fragments of parathyroid autotransplantation, all 4 parathyroids could not be identified. Therefore, 63 patients in the 20-fragment group and 64 patients in the 45-fragment group were included in the analysis. Fig. 2CONSORT flow diagram. CONSORT flow diagram. The baseline characteristics of the analyzed patients, including mean age, gender, duration of hemodialysis, symptoms of hyperparathyroidism, and laboratory results (intact parathyroid hormone, corrected calcium, phosphorus, magnesium, alkaline phosphatase, and creatinine levels), were comparable between the two groups, reflecting the homogeneity of patients (Table 1). Although 87% of patients were kidney transplant candidates, none received transplantation during the follow-up period. Table 1Baseline characteristics of patients who underwent total parathyroidectomy with autotransplantation of 20 or 45 fragments of parathyroid tissue.Variables20-fragment groupn = 6345-fragment groupn = 64p valueGender (%) Male28 (44.4)33 (51.6)0.479 Female35 (55.6)31 (48.4)Age, years (mean ± SD)44.70 ± 13.1146.06 ± 12.410.548Duration of renal failure, year (mean ± SD)8.29 ± 3.058.88 ± 4.130.363Duration of hemodialysis, year (mean ± SD)6.56 ± 3.046.48 ± 2.430.892Symptoms Bone pain (VAS 0–10) (mean ± SD)4.08 ± 2.113.89 ± 2.270.628 Muscle weakness (VAS 0–10) (mean ± SD)2.87 ± 2.252.41 ± 1.850.203 Skin pruritus (VAS 0–10) (mean ± SD)3.67 ± 1.793.38 ± 1.840.368Biochemical results Parathyroid hormone, pg/mL (mean ± SD)2092.16 ± 750.591992.94 ± 627.150.420 Corrected calcium, mg/dL (mean ± SD)9.53 ± 1.089.34 ± 0.820.270 Phosphorus, mg/dL (mean ± SD)4.73 ± 1.354.54 ± 1.430.442 Magnesium, mEq/L (mean ± SD)1.80 ± 0.241.77 ± 0.260.375 Alkaline phosphatase, U/L (mean ± SD)490.78 ± 303.81457.42 ± 240.760.494 Creatinine, mg/dL (mean ± SD)9.39 ± 5.338.60 ± 2.790.295Corrected calcium = Calcium + 0.8 × (4-Albumin).No statistical difference in all variables between the two groups. Table 1Baseline characteristics of patients who underwent total parathyroidectomy with autotransplantation of 20 or 45 fragments of parathyroid tissue.Variables20-fragment groupn = 6345-fragment groupn = 64p valueGender (%) Male28 (44.4)33 (51.6)0.479 Female35 (55.6)31 (48.4)Age, years (mean ± SD)44.70 ± 13.1146.06 ± 12.410.548Duration of renal failure, year (mean ± SD)8.29 ± 3.058.88 ± 4.130.363Duration of hemodialysis, year (mean ± SD)6.56 ± 3.046.48 ± 2.430.892Symptoms Bone pain (VAS 0–10) (mean ± SD)4.08 ± 2.113.89 ± 2.270.628 Muscle weakness (VAS 0–10) (mean ± SD)2.87 ± 2.252.41 ± 1.850.203 Skin pruritus (VAS 0–10) (mean ± SD)3.67 ± 1.793.38 ± 1.840.368Biochemical results Parathyroid hormone, pg/mL (mean ± SD)2092.16 ± 750.591992.94 ± 627.150.420 Corrected calcium, mg/dL (mean ± SD)9.53 ± 1.089.34 ± 0.820.270 Phosphorus, mg/dL (mean ± SD)4.73 ± 1.354.54 ± 1.430.442 Magnesium, mEq/L (mean ± SD)1.80 ± 0.241.77 ± 0.260.375 Alkaline phosphatase, U/L (mean ± SD)490.78 ± 303.81457.42 ± 240.760.494 Creatinine, mg/dL (mean ± SD)9.39 ± 5.338.60 ± 2.790.295Corrected calcium = Calcium + 0.8 × (4-Albumin).No statistical difference in all variables between the two groups. Baseline characteristics of patients who underwent total parathyroidectomy with autotransplantation of 20 or 45 fragments of parathyroid tissue. Corrected calcium = Calcium + 0.8 × (4-Albumin). No statistical difference in all variables between the two groups. Postoperative laboratory and clinical outcomes Parathyroid hormone levels Mean levels of corrected calcium and the amount of specific medications (calcium and vitamin D intake per day) did not differ between the two groups at the postoperative 1st, 3rd, 6th, 12th, 18th, 24th, and 36th months. Although the mean PTH levels in the 45-fragment group were higher than those in the 20-fragment group at all follow-up visits, only the level at the 12 month visit was statistically significant (43.79 pg/mL vs. 32.82 pg/mL, p = 0.044), and the mean PTH levels of the two groups became less different thereafter (Table 2) (Fig. 3). Notably, all the mean PTH levels were within normal limits in both groups. In the multivariable linear regression analysis of PTH levels following adjustment for calcium and vitamin D intake and serum calcium level, there were positive coefficients, indicating that mean PTH levels in the 45-fragment group were higher than those in the 20-fragment group at all follow-up visits as well. However, statistical significance was detected only at the postoperative 12 month follow-up (coefficient 11.43, 95% Confidence interval 0.83–22.02, p = 0.035) (Table 3). Table 2Postoperative intact parathyroid hormone, corrected calcium levels, and amount of calcium and vitamin D intake of the two groups at each follow-up visit.Variables(Follow-up visit)20-fragment groupn = 63 (mean ± SD)45-fragment groupn = 64 (mean ± SD)p valueParathyroid hormone (pg/mL) 1st month15.18 ± 18.7816.63 ± 18.840.664 3rd month27.27 ± 29.7529.03 ± 31.280.749 6th month29.44 ± 37.1340.43 ± 44.300.132 12th month32.82 ± 31.0543.79 ± 29.62 0.044 18th month34.73 ± 31.5338.11 ± 21.590.629 24th month39.37 ± 33.3340.61 ± 21.550.897 36th month37.93 ± 9.9439.82 ± 19.100.487Correct calcium (mg/dL) 1st month9.80 ± 2.0010.03 ± 2.190.547 3rd month9.18 ± 1.589.29 ± 1.600.685 6th month9.34 ± 1.399.37 ± 1.520.910 12th month9.07 ± 1.209.18 ± 0.980.585 18th month9.32 ± 0.959.21 ± 1.250.573 24th month9.23 ± 0.699.06 ± 0.790.203 36th month9.11 ± 0.599.09 ± 0.700.914Amount of calcium intake (mg/day) 1st month9095.86 ± 530.198953.13 ± 375.000.083 3rd month8952.38 ± 377.968859.13 ± 639.120.321 6th month8666.67 ± 950.388578.13 ± 1051.150.620 12th month7190.48 ± 1479.517265.63 ± 1586.070.783 18th month3619.05 ± 1223.803703.13 ± 1280.860.706 24th month3142.86 ± 839.683093.75 ± 750.000.729 36th month857.14 ± 1366.14937.50 ± 1401.530.744Amount of vitamin D intake (mcg/day) 1st month0.42 + 0.120.41 + 0.110.755 3rd month0.40 + 0.120.39 + 0.120.521 6th month0.28 ± 0.080.27 + 0.070.975 12th month0.38 + 0.130.37 + 0.120.790 18th month0.37 + 0.120.37 ± 0.130.929 24th month0.32 + 0.120.29 + 0.100.162 36th month0.07 + 0.110.08 + 0.110.744Student’s t-test.Bold value indicates statistically significant. Table 2Postoperative intact parathyroid hormone, corrected calcium levels, and amount of calcium and vitamin D intake of the two groups at each follow-up visit.Variables(Follow-up visit)20-fragment groupn = 63 (mean ± SD)45-fragment groupn = 64 (mean ± SD)p valueParathyroid hormone (pg/mL) 1st month15.18 ± 18.7816.63 ± 18.840.664 3rd month27.27 ± 29.7529.03 ± 31.280.749 6th month29.44 ± 37.1340.43 ± 44.300.132 12th month32.82 ± 31.0543.79 ± 29.62 0.044 18th month34.73 ± 31.5338.11 ± 21.590.629 24th month39.37 ± 33.3340.61 ± 21.550.897 36th month37.93 ± 9.9439.82 ± 19.100.487Correct calcium (mg/dL) 1st month9.80 ± 2.0010.03 ± 2.190.547 3rd month9.18 ± 1.589.29 ± 1.600.685 6th month9.34 ± 1.399.37 ± 1.520.910 12th month9.07 ± 1.209.18 ± 0.980.585 18th month9.32 ± 0.959.21 ± 1.250.573 24th month9.23 ± 0.699.06 ± 0.790.203 36th month9.11 ± 0.599.09 ± 0.700.914Amount of calcium intake (mg/day) 1st month9095.86 ± 530.198953.13 ± 375.000.083 3rd month8952.38 ± 377.968859.13 ± 639.120.321 6th month8666.67 ± 950.388578.13 ± 1051.150.620 12th month7190.48 ± 1479.517265.63 ± 1586.070.783 18th month3619.05 ± 1223.803703.13 ± 1280.860.706 24th month3142.86 ± 839.683093.75 ± 750.000.729 36th month857.14 ± 1366.14937.50 ± 1401.530.744Amount of vitamin D intake (mcg/day) 1st month0.42 + 0.120.41 + 0.110.755 3rd month0.40 + 0.120.39 + 0.120.521 6th month0.28 ± 0.080.27 + 0.070.975 12th month0.38 + 0.130.37 + 0.120.790 18th month0.37 + 0.120.37 ± 0.130.929 24th month0.32 + 0.120.29 + 0.100.162 36th month0.07 + 0.110.08 + 0.110.744Student’s t-test.Bold value indicates statistically significant. Postoperative intact parathyroid hormone, corrected calcium levels, and amount of calcium and vitamin D intake of the two groups at each follow-up visit. Student’s t-test. Bold value indicates statistically significant. Fig. 3Comparison of the mean parathyroid hormone levels of the two groups over time. Comparison of the mean parathyroid hormone levels of the two groups over time. Table 3Multivariable linear regression analysis of parathyroid hormone levels of the 45-fragment group compared with the 20-fragment group, calculated following adjustment for the amount of calcium and vitamin D intake and serum calcium level at each follow-up visit.Follow-up visitCoefficients(95% confidence interval)p value1st month1.75 (− 4.71–8.22)0.5923rd month3.44 (− 6.05–12.93)0.4746th month11.08 (− 2.73–24.88)0.11512th month11.43 (0.83–22.02) 0.035 18th month2.50 (− 11.20–16.20)0.71824th month1.83 (− 17.58–21.23)0.80336th month1.81 (− 3.52–7.14)0.853Bold value indicates statistically significant. Table 3Multivariable linear regression analysis of parathyroid hormone levels of the 45-fragment group compared with the 20-fragment group, calculated following adjustment for the amount of calcium and vitamin D intake and serum calcium level at each follow-up visit.Follow-up visitCoefficients(95% confidence interval)p value1st month1.75 (− 4.71–8.22)0.5923rd month3.44 (− 6.05–12.93)0.4746th month11.08 (− 2.73–24.88)0.11512th month11.43 (0.83–22.02) 0.035 18th month2.50 (− 11.20–16.20)0.71824th month1.83 (− 17.58–21.23)0.80336th month1.81 (− 3.52–7.14)0.853Bold value indicates statistically significant. Multivariable linear regression analysis of parathyroid hormone levels of the 45-fragment group compared with the 20-fragment group, calculated following adjustment for the amount of calcium and vitamin D intake and serum calcium level at each follow-up visit. Bold value indicates statistically significant. Symptoms of hyperparathyroidism Both groups had amelioration of bone pain, muscle weakness, and skin pruritus over time. However, patients in the 45-fragment group had significantly greater improvement in bone pain and skin pruritus at the postoperative 12th and 18th months than those in the 20-fragment group in the nonparametric statistical test (Mann-Whitney U test) (Fig. 4). Fig. 4Box plot of the visual analog scale scores of bone pain (A), muscle weakness (B), and skin pruritus (C) of the two groups over time. Box plot of the visual analog scale scores of bone pain (A), muscle weakness (B), and skin pruritus (C) of the two groups over time. Persistent/recurrent hyperparathyroidism and permanent hypoparathyroidism There was no persistent or recurrent hyperparathyroidism in the 45-fragment group. A patient in the 20-fragment group had PTH levels of 419 and 604 pg/mL at the postoperative 12th and 18th months, respectively. After the modified Casanova test was performed, it was revealed that the ischemic PTH level decreased by more than 50% of the preischemic value (test positive), indicating the source of the parathyroid hormone at the tibialis muscle. The patient had the transplanted parathyroid removed, and the PTH returned to normal after surgery (16 pg/mL at the 36th month). In addition, 2 (3.17%) patients in the 20-fragment group and 1 (1.56%) patient in the 45-fragment group experienced hypoparathyroidism requiring calcium and calcitriol replacement without clinical signs of adynamic bone disease at the end of the follow-up period. Complications and duration of hospitalization Postoperative complications occurred in 3 patients in the 20-fragment group: 1 had bleeding at the wound edge, treated with re-suture, 1 had a chylous fistula, which was successfully controlled with conservative treatment, and the other had 2 months of temporary unilateral vocal cord paralysis. In the 45-fragment group, complications were observed in 4 patients: 1 had a hematoma, which was treated with blood evacuation and small vessel cauterization; 2 had unilateral vocal cord paralysis, which spontaneously recovered 3 and 4 months later; and 1 had thrombophlebitis at the venous catheter site. No complication was observed at the implanted site in either group. The mean duration of hospitalization did not differ between the two groups (8.24 days in the 20-fragment group and 7.75 days in the 45-fragment group, p = 0.545) (Table 4). Table 4Postoperative complications and duration of hospitalization in both groups.Variables20-fragment groupn = 63 (%)45-fragment groupn = 64 (%)p valueComplications3 (4.8)4 (6.3)1.000Duration of hospitalization, day (mean ± SD)8.24 ± 6.047.75 ± 2.210.545 Table 4Postoperative complications and duration of hospitalization in both groups.Variables20-fragment groupn = 63 (%)45-fragment groupn = 64 (%)p valueComplications3 (4.8)4 (6.3)1.000Duration of hospitalization, day (mean ± SD)8.24 ± 6.047.75 ± 2.210.545 Postoperative complications and duration of hospitalization in both groups. Discussion During the period of 36 months following TPTX-AT, mean serum PTH levels in patients with the 45-fragment group were higher than those in the 20-fragment group at all 7 follow-up visits. However, the difference was statistically significant only at the postoperative 12th month (43.79 pg/mL vs. 32.82 pg/mL, p = 0.044). In addition, after that time, the mean PTH levels of the two groups became less different. Notably, mean PTH levels in both groups were within the normal range at all follow-up visits. Following the multivariable linear regression analysis, controlling for the effects of calcium and vitamin D intakes and serum calcium level, the positive coefficients indicated that the adjusted mean PTH levels of patients in the 45-fragment group were higher than those in the 20-fragment group at all follow-up visits. However, a statistical difference was only demonstrated at the postoperative 12th month (coefficient 11.43, 95% CI 0.83–22.02, p = 0.035), and the differences between groups gradually decreased over time thereafter. This denotes that patients in the 45-fragment group may not have a higher risk of developing recurrent hyperparathyroidism in the long term. Regarding symptoms of hyperparathyroidism, bone pain, muscle weakness, and skin pruritus were ameliorated over time in both groups. However, patients in the 45-fragment group had significantly less bone pain and skin pruritus at the 12th and 18th months than those in the 20-fragment group. This may be explained by the higher rate of PTH recovery in the 45-fragment group, which reached the maximal effect at the 12th month. The influence of the amount of autotransplantation on these improved symptoms subsided afterward. Recurrent hyperparathyroidism was detected in one (1.58%) patient in the 20-fragment group at the postoperative 12th month. After confirming with the modified Casanova test, the patient was successfully treated by removing the autotransplanted parathyroid. Notably, no patient in the 45-fragment group encountered persistence or recurrence. The recurrent and reoperative rates in this study are fewer than in most of the previous studies performing TPTX-AT with transcervical thymectomy when indicated (when fewer than 2 parathyroid glands were intraoperatively detected on that side) or without thymectomy at all, with the average recurrent rate of 9.35% (range 0-28.57%) and the average reoperative rate of 8.08% (range 0-28.57%)13,14,16,18–20,22–25,30–33. In addition, recurrence from the autograft was reported at the average rate of 74.21% (range 25–100%)14,20,22–25,30. Persistent or recurrent hyperparathyroidism may be caused by an ectopic gland, supernumerary glands, or overgrowth of a remnant or parathyroid autograft following parathyroidectomy6. In non-kidney transplanted patients, remnant parathyroid tissue may be persistently stimulated, thus causing the tissue to increase in size and inducing the recurrence of hyperparathyroidism6. Since no patients had renal transplantation during the study period, the procedures used in this study are considered safe in this group of patients. In addition, 2 (3.17%) patients in the 20-fragment group and 1 (1.56%) patient in the 45-fragment group developed permanent hypoparathyroidism, rates that were relatively low in comparison with previous reports of TPTX-AT with limited or no thymectomy, which ranged from 3.57 to 20%13,14,18,20,33. Postoperative complications were detected at a similar rate between the two groups. Temporary vocal cord paralysis was observed in 1 (1.58%) patient in the 20-fragment group and 2 (3.12%) patients in the 45-fragment group, and minor bleeding was observed in 1 patient in each group (1.58% in the 20-fragment group and 1.56% in the 45-fragment group). These complication rates were consistent with previous studies, which reported 1-8.03% of recurrent laryngeal nerve palsy and 0.5–2.08% of postoperative hemorrhage7,17,24,26. In addition, the duration of hospitalization also did not differ between groups (8.24 days in the 20-fragment group and 7.75 days in the 45-fragment group). There are some limitations in the study. First, calcium levels in the dialysis fluids in each patient were unknown due to differences in dialysis centers. Second, disease recurrence was detected at the autograft only; however, the study did not test the effect of routine thymectomy on the recurrence. Third, although the mean PTH differences between groups gradually decreased over time and became much less at the 36th month, a longer-term follow-up is warranted. Conclusion Total parathyroidectomy with autotransplantation of either 20 or 45 fragments of 1 mm3 parathyroid tissue at the anterior tibialis muscle provides similar mean PTH levels at the postoperative 36th month, and comparable low rates of recurrence, reoperation, hypoparathyroidism, and complications. Although transplantation of 45 fragments of parathyroid resulted in significantly greater improvement of the PTH level at the 12th month and the hyperparathyroidism symptoms at the 12th and 18th months, both 20 and 45 parathyroid fragment transplantation appeared to be effective and safe procedures for patients with secondary hyperparathyroidism without kidney transplantation. However, large multicenter trials and a long-term follow-up are required to confirm the results.